



7 February 2024
EMA/137143/2023 Rev. 1¹

Shortage of Ixiaro (Japanese encephalitis vaccine (inactivated, adsorbed)) suspension for injection	
Indication	Ixiaro is a vaccine used in adults and children aged 2 months and older to help protect against Japanese encephalitis, a disease that causes inflammation of the brain.
Reason for shortage	The company that markets Ixiaro is experiencing manufacturing problems. This affects an existing shortage of Ixiaro resulting from an increase in demand. The shortage is expected to last until June 2024 in most EU/EEA countries. The shortage is not related to a safety issue.
Member States affected	The supply shortage affects all EU/EEA Member States. For up-to-date information about the status of a medicine shortage in a particular EU/EEA Member State, consult the national shortage register or contact the national competent authority .
Monitoring of shortage	EMA's SPOC working party is closely monitoring the supply situation and engaging with the marketing authorisation holder to identify measures to mitigate the impact of the supply shortage. Summaries of the SPOC working party meetings can be found on EMA's website .
Information for healthcare professionals	<ul style="list-style-type: none">• The company holding the marketing authorisation for Ixiaro, Valneva Austria GmbH, is experiencing manufacturing problems. This is impacting on an already existing shortage of Ixiaro due to an increase in demand and has led to a shortage of the vaccine in all EU/EEA Member States.• Please consult your country's national shortage register for further advice, including advice on the availability of Ixiaro in your country.
Information for public	<ul style="list-style-type: none">• The company holding the marketing authorisation for Ixiaro is experiencing manufacturing problems. This is

¹ This document was first published on 25 May 2023. It was modified on 7 February 2024 to include information about a manufacturing problem impacting an already existing shortage and to update the Member States affected.



Shortage of Ixiaro (Japanese encephalitis vaccine (inactivated, adsorbed)) suspension for injection

	<p>impacting on an already existing shortage of Ixiaro due to an increase in demand and has led to a shortage of the vaccine in all EU/EEA Member States.</p> <ul style="list-style-type: none">• Please consult your doctor or pharmacist for any questions and for advice on current availability of Ixiaro.• Alternatively you can also consult your country's national shortage register for further information.
Status	Ongoing